Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study
Background - Earlier diagnosis of pancreatic ductal adenocarcinoma is key to improving overall survival in patients with this hard-to-treat cancer. We independently validated two previously identified plasma-based metabolic signatures for exclusion of pancreatic ductal adenocarcinoma in cohorts with...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2025
|
| In: |
The lancet. Gastroenterology & Hepatology
Year: 2025, Jahrgang: 10, Heft: 7, Pages: 634-647 |
| ISSN: | 2468-1156 |
| DOI: | 10.1016/S2468-1253(25)00056-1 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/S2468-1253(25)00056-1 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2468125325000561 
|
| Verfasserangaben: | Ujjwal M Mahajan, Bettina Oehrle, Elisabetta Goni, Oliver Strobel, Jörg Kaiser, Robert Grützmann, Jens Werner, Helmut Friess, Thomas M Gress, Thomas W Seufferlein, Waldemar Uhl, Uwe Will, John P Neoptolemos, Uwe A Wittel, Marlies Vornhülz, Simon Sirtl, Georg Beyer, Ivonne Regel, Stefan Boeck, Volker Heinemann, Fabian Frost, Antje Steveling, Henry Völzke, Astrid Petersmann, Matthias Nauck, Eckhard Weber, Beate Kamlage, Markus M Lerch, Julia Mayerle, for the METAPAC trial investigators |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1949876020 | ||
| 003 | DE-627 | ||
| 005 | 20260121115251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260121s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2468-1253(25)00056-1 |2 doi | |
| 035 | |a (DE-627)1949876020 | ||
| 035 | |a (DE-599)KXP1949876020 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mahajan, Ujwal Mukund |d 1986- |e VerfasserIn |0 (DE-588)108400819X |0 (DE-627)848078330 |0 (DE-576)455765278 |4 aut | |
| 245 | 1 | 0 | |a Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC) |b a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study |c Ujjwal M Mahajan, Bettina Oehrle, Elisabetta Goni, Oliver Strobel, Jörg Kaiser, Robert Grützmann, Jens Werner, Helmut Friess, Thomas M Gress, Thomas W Seufferlein, Waldemar Uhl, Uwe Will, John P Neoptolemos, Uwe A Wittel, Marlies Vornhülz, Simon Sirtl, Georg Beyer, Ivonne Regel, Stefan Boeck, Volker Heinemann, Fabian Frost, Antje Steveling, Henry Völzke, Astrid Petersmann, Matthias Nauck, Eckhard Weber, Beate Kamlage, Markus M Lerch, Julia Mayerle, for the METAPAC trial investigators |
| 264 | 1 | |c July 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 16. Mai 2025, Artikelversion: 4. Juni 2025 | ||
| 500 | |a Gesehen am 21.01.2026 | ||
| 520 | |a Background - Earlier diagnosis of pancreatic ductal adenocarcinoma is key to improving overall survival in patients with this hard-to-treat cancer. We independently validated two previously identified plasma-based metabolic signatures for exclusion of pancreatic ductal adenocarcinoma in cohorts with an increased annual risk. - Methods - The METAPAC study was a prospective, multicentre, investigator-masked, enrichment design, phase 4 trial done in 23 centres in Germany. Patients with pancreatic lesions identified by diagnostic imaging that required further diagnostic assessment were recruited and followed up for 24 months. Targeted quantitative plasma metabolite analysis was done on a liquid chromatography-tandem mass spectrometry platform. The improved metabolic (i-Metabolic) signature consisted of 12 analytes plus carbohydrate antigen (CA) 19-9, and the minimalistic metabolic (m-Metabolic) signature consisted of four analytes plus CA 19-9. The primary endpoint of the study was the exclusion of pancreatic ductal adenocarcinoma with an 85% specificity and the highest possible diagnostic accuracy. All statistical analyses were done per protocol. This study is registered with the German Clinical Trials Register (DRKS00010866). - Findings - Between Sept 9, 2016, and April 8, 2022, 1370 patients with CT-identified pancreatic lesions necessitating further diagnostic assessment were screened, of whom 1129 patients (489 with pancreatic ductal adenocarcinoma, 640 controls) were included in the primary analysis (median age 67 years [IQR 58-75]; 556 [49%] female, 572 [51%] male). The control group consisted of high-risk individuals with acute pancreatitis (11 [1%] of 1129 participants), chronic pancreatitis (113 [10%]), intraductal papillary mucinous neoplasms (232 [21%]), cystic lesions other than intraductal papillary mucinous neoplasms (271 [24%]), and metastases of extrapancreatic origin (13 [1%]). The i-Metabolic signature detected pancreatic ductal adenocarcinoma with an area under the curve (AUC) of 0·846 (95% CI 0·842-0·849), specificity of 90·4% (89·8-91·1), sensitivity of 67·5% (66·9-68·0), and balanced accuracy of 80·5% (80·2-80·8), compared with CA 19-9 alone (AUC 0·799 [0·797-0·802], p<0·0001; specificity 79·1% [78·7-79·4]; sensitivity 81·8% [81·5-82·0]; balanced accuracy 80·6% [80·4-80·9]). The m-Metabolic signature detected pancreatic ductal adenocarcinoma with an AUC of 0·846 (95% CI 0·842-0·849; p<0·0001 vs CA 19-9 alone), specificity of 93·6% (93·1-94·0), sensitivity of 59·9% (59·3-60·4), and accuracy of 79·0% (78·8-79·2). In a population of 242 individuals with new-onset diabetes (three cases of incident pancreatic ductal adenocarcinoma), the m-Metabolic signature (without CA 19-9) significantly discriminated patients with pancreatic ductal adenocarcinoma from those without (p=0·038). AUC, specificity, and sensitivity remained constant after random bootstrapping for a prevalence of pancreatic ductal adenocarcinoma between 1% and 20%. - Interpretation - Two plasma-based metabolic signatures showed significant improvement in performance compared with CA 19-9 alone in excluding pancreatic ductal adenocarcinoma in a prospective real-world cohort. These findings could offer a surveillance tool in patients with an annual risk of pancreatic ductal adenocarcinoma of 1% to reduce unnecessary invasive procedures and facilitate earlier detection of resectable disease. - Funding - Federal Ministry of Education and Research (BMBF, Germany). | ||
| 700 | 1 | |a Oehrle, Bettina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goni, Elisabetta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Strobel, Oliver |d 1974- |e VerfasserIn |0 (DE-588)123658977 |0 (DE-627)706385101 |0 (DE-576)293812357 |4 aut | |
| 700 | 1 | |a Kaiser, Jörg |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grützmann, Robert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Werner, Jens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Friess, Helmut |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gress, Thomas M |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seufferlein, Thomas W |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uhl, Waldemar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Will, Uwe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Neoptolemos, John P. |e VerfasserIn |0 (DE-588)172283302 |0 (DE-627)697192954 |0 (DE-576)133150879 |4 aut | |
| 700 | 1 | |a Wittel, Uwe A |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vornhülz, Marlies |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sirtl, Simon |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beyer, Georg |e VerfasserIn |4 aut | |
| 700 | 1 | |a Regel, Ivonne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boeck, Stefan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinemann, Volker |e VerfasserIn |4 aut | |
| 700 | 1 | |a Frost, Fabian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Steveling, Antje |e VerfasserIn |4 aut | |
| 700 | 1 | |a Völzke, Henry |e VerfasserIn |4 aut | |
| 700 | 1 | |a Petersmann, Astrid |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nauck, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weber, Eckhard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kamlage, Beate |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lerch, Markus M |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mayerle, Julia |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Gastroenterology & Hepatology |d London : Elsevier, 2016 |g 10(2025), 7 vom: Juli, Seite 634-647 |h Online-Ressource |w (DE-627)872465713 |w (DE-600)2874542-5 |w (DE-576)479746354 |x 2468-1156 |7 nnas |a Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC) a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study |
| 773 | 1 | 8 | |g volume:10 |g year:2025 |g number:7 |g month:07 |g pages:634-647 |g extent:14 |a Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC) a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S2468-1253(25)00056-1 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2468125325000561 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260121 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 172283302 |a Neoptolemos, John P. |m 172283302:Neoptolemos, John P. |d 910000 |d 910200 |e 910000PN172283302 |e 910200PN172283302 |k 0/910000/ |k 1/910000/910200/ |p 13 | ||
| 998 | |g 123658977 |a Strobel, Oliver |m 123658977:Strobel, Oliver |d 50000 |e 50000PS123658977 |k 0/50000/ |p 4 | ||
| 999 | |a KXP-PPN1949876020 |e 4855705845 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Ujwal Mukund","display":"Mahajan, Ujwal Mukund","role":"aut","roleDisplay":"VerfasserIn","family":"Mahajan"},{"given":"Bettina","display":"Oehrle, Bettina","role":"aut","family":"Oehrle","roleDisplay":"VerfasserIn"},{"given":"Elisabetta","role":"aut","display":"Goni, Elisabetta","family":"Goni","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Strobel","given":"Oliver","role":"aut","display":"Strobel, Oliver"},{"family":"Kaiser","roleDisplay":"VerfasserIn","display":"Kaiser, Jörg","role":"aut","given":"Jörg"},{"role":"aut","display":"Grützmann, Robert","given":"Robert","family":"Grützmann","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Werner","display":"Werner, Jens","role":"aut","given":"Jens"},{"role":"aut","display":"Friess, Helmut","given":"Helmut","family":"Friess","roleDisplay":"VerfasserIn"},{"display":"Gress, Thomas M","role":"aut","given":"Thomas M","roleDisplay":"VerfasserIn","family":"Gress"},{"given":"Thomas W","display":"Seufferlein, Thomas W","role":"aut","roleDisplay":"VerfasserIn","family":"Seufferlein"},{"family":"Uhl","roleDisplay":"VerfasserIn","display":"Uhl, Waldemar","role":"aut","given":"Waldemar"},{"display":"Will, Uwe","role":"aut","given":"Uwe","roleDisplay":"VerfasserIn","family":"Will"},{"roleDisplay":"VerfasserIn","family":"Neoptolemos","display":"Neoptolemos, John P.","role":"aut","given":"John P."},{"given":"Uwe A","role":"aut","display":"Wittel, Uwe A","family":"Wittel","roleDisplay":"VerfasserIn"},{"family":"Vornhülz","roleDisplay":"VerfasserIn","role":"aut","display":"Vornhülz, Marlies","given":"Marlies"},{"family":"Sirtl","roleDisplay":"VerfasserIn","given":"Simon","display":"Sirtl, Simon","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Beyer","given":"Georg","display":"Beyer, Georg","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Regel","given":"Ivonne","display":"Regel, Ivonne","role":"aut"},{"given":"Stefan","role":"aut","display":"Boeck, Stefan","family":"Boeck","roleDisplay":"VerfasserIn"},{"given":"Volker","role":"aut","display":"Heinemann, Volker","roleDisplay":"VerfasserIn","family":"Heinemann"},{"roleDisplay":"VerfasserIn","family":"Frost","role":"aut","display":"Frost, Fabian","given":"Fabian"},{"role":"aut","display":"Steveling, Antje","given":"Antje","roleDisplay":"VerfasserIn","family":"Steveling"},{"role":"aut","display":"Völzke, Henry","given":"Henry","family":"Völzke","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Petersmann","given":"Astrid","role":"aut","display":"Petersmann, Astrid"},{"role":"aut","display":"Nauck, Matthias","given":"Matthias","roleDisplay":"VerfasserIn","family":"Nauck"},{"role":"aut","display":"Weber, Eckhard","given":"Eckhard","family":"Weber","roleDisplay":"VerfasserIn"},{"display":"Kamlage, Beate","role":"aut","given":"Beate","family":"Kamlage","roleDisplay":"VerfasserIn"},{"family":"Lerch","roleDisplay":"VerfasserIn","display":"Lerch, Markus M","role":"aut","given":"Markus M"},{"family":"Mayerle","roleDisplay":"VerfasserIn","given":"Julia","role":"aut","display":"Mayerle, Julia"}],"name":{"displayForm":["Ujjwal M Mahajan, Bettina Oehrle, Elisabetta Goni, Oliver Strobel, Jörg Kaiser, Robert Grützmann, Jens Werner, Helmut Friess, Thomas M Gress, Thomas W Seufferlein, Waldemar Uhl, Uwe Will, John P Neoptolemos, Uwe A Wittel, Marlies Vornhülz, Simon Sirtl, Georg Beyer, Ivonne Regel, Stefan Boeck, Volker Heinemann, Fabian Frost, Antje Steveling, Henry Völzke, Astrid Petersmann, Matthias Nauck, Eckhard Weber, Beate Kamlage, Markus M Lerch, Julia Mayerle, for the METAPAC trial investigators"]},"physDesc":[{"noteIll":"Illustrationen","extent":"14 S."}],"relHost":[{"disp":"Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC) a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic studyThe lancet. Gastroenterology & Hepatology","id":{"zdb":["2874542-5"],"eki":["872465713"],"issn":["2468-1156"]},"title":[{"title_sort":"lancet","title":"The lancet","partname":"Gastroenterology & Hepatology"}],"recId":"872465713","titleAlt":[{"title":"Gastroenterology and hepatology"}],"pubHistory":["Volume 1, issue 1 (September 2016)-"],"titleUni":[{"title":"The lancet (London)"}],"language":["eng"],"origin":[{"publisher":"Elsevier","publisherPlace":"London","dateIssuedDisp":"[2016]-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"issue":"7","volume":"10","text":"10(2025), 7 vom: Juli, Seite 634-647","pages":"634-647","extent":"14","year":"2025"},"physDesc":[{"extent":"Online-Ressource"}]}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"July 2025","dateIssuedKey":"2025"}],"id":{"eki":["1949876020"],"doi":["10.1016/S2468-1253(25)00056-1"]},"title":[{"subtitle":"a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study","title_sort":"Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC)","title":"Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC)"}],"recId":"1949876020","note":["Online verfügbar: 16. Mai 2025, Artikelversion: 4. Juni 2025","Gesehen am 21.01.2026"]} | ||
| SRT | |a MAHAJANUJWVALIDATION2025 | ||